Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 1/20 | 0.43 |
| ▸ | SRC | P12931 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | MMP1 | P03956 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | MMP3 | P08254 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
| ▸ | MMP8 | P22894 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | METAP1 | P53582 | 1/20 | 0.38 |
| ▸ | SLC1A3 | P43003 | 3/20 | 0.36 |
| ▸ | SLC1A2 | P43004 | 3/20 | 0.36 |
| ▸ | SLC1A1 | P43005 | 3/20 | 0.36 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.34 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6026930 | 0.98 | SRC (0.45) | FBP1SRCCA12CA1CA2 | |
| SCHEMBL27276638 | 0.96 | SRC (0.44) | FBP1SRCCA12CA1CA2 | |
| SCHEMBL11520489 | 0.90 | — | — | |
| SCHEMBL779199 | 0.82 | SRC (0.41) | SRCCA12CA1CA2MMP1 | |
| SCHEMBL17898545 | 0.81 | NAAA (0.38) | SRCCA12CA1CA2MMP1 | |
| SCHEMBL23884945 | 0.80 | SRC (0.43) | SRCCA12CA1CA2MMP1 | |
| SCHEMBL3490419 | 0.80 | FBP1 (0.39) | FBP1SRC | |
| SCHEMBL3426411 | 0.80 | ANPEP (0.42) | FBP1LMNA | |
| SCHEMBL779866 | 0.80 | SRC (0.43) | SRCCA12CA1CA2MMP1 | |
| SCHEMBL1885137 | 0.80 | SRC (0.43) | SRCCA12CA1CA2MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7691867-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2010-04-06 | — | — | US | disclosed |
| EP-1635837-B1 | (3-((QUINAZOLIN-4-YL)AMINO)-1H-PYRAZOL-1-YL)ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS AURORA KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES SUCH AS CANCER | ASTRAZENECA AB (SE) | 2008-07-16 | — | — | EP | disclosed |
| EP-1613619-B1 | QUINAZOLINE DERIVATIVES FOR TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2008-03-26 | — | — | EP | disclosed |
| US-20060270692-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2006-11-30 | — | — | US | disclosed |
| US-20060178382-A1 | Chinazoline derivatives as aurora kinase inhibitors | ASTRAZENECA AB (SE) | 2006-08-10 | — | — | US | disclosed |
| US-20060135541-A1 | (3-((Quinazolin-4-yl) amino)-1h-pyrazol-1-yl)acetamide derivatives and related compounds as aurora kinase inhibitors for the treatment of proliferative diseases such as cancer | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | US | disclosed |
| EP-1644361-A1 | CHINAZOLINE DERIVATIVES AS AURORA KINASE INHIBITORS | Astrazeneca AB (SE) | 2006-04-12 | — | — | EP | disclosed |
| EP-1635837-A1 | (3-((QUINAZOLIN-4-YL)AMINO)-1H-PYRAZOL-1-YL)ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS AURORA KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES SUCH AS CANCER | AstraZeneca AB (SE) | 2006-03-22 | — | — | EP | disclosed |
| EP-1613619-A1 | QUINAZOLINE DERIVATIVES FOR TREATMENT OF CANCER | AstraZeneca AB (SE) | 2006-01-11 | — | — | EP | disclosed |
| WO-2004113324-A1 | CHINAZOLINE DERIVATIVES AS AURORA KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2004-12-29 | — | — | WO | disclosed |
| WO-2004105764-A1 | (3- ((QUINAZOLIN-4-YL) AMINO )-1H-PYRAZOL-1-YL) ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS AURORA KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES SUCH AS CANCER | ASTRAZENECA AB (SE) | 2004-12-09 | — | — | WO | disclosed |
| WO-2004094410-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2004-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178382-A1 | Chinazoline derivatives as aurora kinase inhibitors | AURKA, AURKC, AURKB | FBP1 3682/4885SRC 451/4885CA12 4143/4885 |
| US-20060135541-A1 | (3-((Quinazolin-4-yl) amino)-1h-pyrazol-1-yl)acetamide derivatives and related compounds as aurora kinase inhibitors for the treatment of proliferative diseases such as cancer | CDK19, CDK16, AURKC | FBP1 4628/4885SRC 798/4885CA12 3688/4885 |
| US-20060270692-A1 | Chemical compounds | CCNI, MKI67, TP53 | FBP1 1916/4885SRC 2439/4885CA12 2846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.